今年是武田製藥進入中國30周年。「武田將繼續深耕上海，並進一步加大投資,積極利用上海雄厚的人才資源和規範開放的經營環境。」武田製藥全球高級副總裁、武田中國總裁單國洪認為，駐華跨國葯企可以成為一個開放包容的交流橋樑，促進上海本地企業和重要外資企業進行交流合作，分享並汲取更多經驗和資源，可以穩步開展各項跨國產業合作項目。
This year marks the 30th anniversary of Takeda Pharmaceutical's entry into China. "Takeda will continue to cultivate in Shanghai, further increase investment, and actively utilize Shanghai's abundant human resources and well-ordered and open business environment." Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical and President of Takeda China, believes that multinational pharmaceutical companies in China can become an open and inclusive communication bridge, promote exchanges and cooperation between local enterprises in Shanghai and important foreign-funded enterprises, share and learn more experience and resources, and can steadily carry out various transnational industrial cooperation projects.
03
建議未來持續推動統籌調度機制
Continue to promote the overall scheduling mechanism
上海市商務委制定了全市統籌推進外商投資促進工作實施方案，並希望與重要外資企業建立「投資上海」網路。單國洪認為，這是一項十分利好外企的政策，體現了上海市政府對優化營商環境、促進外資發展的高度重視。該機制的建立將有利於進一步提升外商投資便利化水平，為外企提供更加高效、便捷的服務，從而吸引更多外資落戶上海。」
The Shanghai Municipal Commission of Commerce has formulated an implementation plan for the city's overall promotion of foreign investment, and hopes to propose an "investment in Shanghai" network with important foreign-funded enterprises. Shan Guohong believes that this is a very favorable policy for foreign companies, reflecting the great importance the Shanghai Municipal People's Government attaches to optimizing the business environment and promoting the development of foreign investment. The establishment of this mechanism will help further improve the level of foreign investment facilitation, provide more efficient and convenient services for foreign enterprises, and thus attract more foreign capital to settle in Shanghai."
上海進一步推動基因治療科技創新和產業高質量發展，加快打造生物醫藥產業高地，持續深化與落實相關產業促進精神。單國洪建議，上海以基因治療的准入支付創新為抓手，從三方面出發：一是上海未來可以持續推動統籌調度機制，建立服務專班，健全統籌協調機制，明確各部門職責分工，壓實工作責任。二是為確保機制高效運轉，定期召開統籌調度會議，明確問題受理、流轉、辦理、反饋等環節和時限，確保問題及時高效解決。三是用好用足浦東新區法規立法權，探索基因治療的准入支付創新，爭取先行先試、取得突破。
Shanghai further promotes gene therapy technology innovation and high-quality industrial development, accelerates the creation of a highland for the biomedical industry, and continues to deepen and implement the spirit of promoting related industries. Shan Guohong suggested that Shanghai should focus on the innovation of access and payment for gene therapy, starting from three aspects: First, Shanghai can continue to promote the overall planning mechanism in the future, establish special service departments, improve the overall planning and coordination mechanism, and clarify the division of responsibilities of various departments to implement work responsibilities. Second, in order to ensure the efficient operation of the mechanism, regular overall planning and scheduling meetings should be held to clarify the links and time limits of problem acceptance, transmission, handling, and feedback, so as to ensure that problems are resolved in a timely and efficient manner. Third, Shanghai should make good use of the legislative power of Pudong New Area, explore the access and payment innovation of gene therapy, and strive to try first and make breakthroughs.
04
致力與中國合作夥伴共同構建創新生態圈
Committed to building an innovation ecosystem with our partners
「對外合作」一直是武田製藥的核心研發戰略之一。在全球範圍內，武田製藥積極尋求與社會各界合作，通過多元化的合作模式來加強創新。目前，武田製藥有超過200多個的戰略合作夥伴;這樣的合作也為武田製藥的研髮帶來了許多成果和機遇。
"Foreign cooperation" has always been one of the core R&D strategies of Takeda Pharmaceutical. Globally, Takeda Pharmaceutical actively seeks cooperation with all sectors of society to strengthen innovation through diversified cooperation models. At present, Takeda Pharmaceutical has more than 200 strategic partners, and the cooperation brought by these partners has also brought many achievements and opportunities to the research and development of Takeda Pharmaceutical.
在中國，武田製藥致力於與中國合作夥伴共同構建創新生態圈，不斷擴大與本土企業的合作範圍。這些合作對中國創新加速融入全球創新體系，並成為全球重要的醫藥創新源頭之一將會起到重要的推動作用。
In China, Takeda Pharmaceutical is committed to building an innovation ecosystem with Chinese partners and continuously expanding the scope of cooperation with local companies. These collaborations will play an important role in promoting the integration of Chinese innovation into the global innovation system and becoming one of the important sources of pharmaceutical innovation in the world.
無論是幫助上海企業走出去，還是幫助吸引更多企業投資落戶上海，單國洪認為,駐華跨國葯企可以成為一個開放包容的交流橋樑，促進上海本地企業和重要外資企業進行交流合作，分享並汲取更多經驗和資源，「我們可以穩步開展各項跨國產業合作項目，促進中國的技術創新和中外人才交流，進一步提升上海的產業競爭力和吸引力。同時，通過這個跨國橋樑，上海的企業可以積極地走出去，去世界舞台展示自己的風采，讓世界更多地認識我們，認可我們。」
Whether it is helping Shanghai enterprises to go global or helping attract more enterprises to invest and settle in Shanghai, Shan Guohong believes that multinational pharmaceutical enterprises in China can become an open and inclusive communication bridge, promote exchanges and cooperation between local enterprises in Shanghai and important foreign-funded enterprises, share and learn more experience and resources, "We can steadily carry out various transnational industrial cooperation projects, promote China's technological innovation and the exchange of Chinese and foreign talents, and further enhance Shanghai's industrial competitiveness and attractiveness. At the same time, through this transnational bridge, Shanghai enterprises can actively go out, show their demeanor on the world stage, and let the world know more about us and recognize us.
武田製藥希望與更多國內及上海的本土合作夥伴深入交流，多元化嫁接市場資源，落地創新成果，助力中國創新葯乘風出海，為上海乃至中國醫藥事業的高質量發展貢獻力量。
Takeda Pharmaceutical hopes to have in-depth exchanges with more local partners in China and Shanghai, diversify market resources, implement innovative achievements , help Chinese innovative drugs take advantage of the development trends and go overseas, and contribute to the high-quality development of Shanghai and even China's pharmaceutical industry.
（完）
來源：「投資上海」雜誌
